Biotech’s Big Bets: Off-Label Wins and Setbacks
Kilder
- fiercebiotech.com: Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS - Fierce Biotech
- biopharmadive.com: Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers - BioPharma Dive
- biospace.com: BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut - BioSpace
- Biospace: J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer - BioSpace
- biospace.com: J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer - BioSpace
- nature.com: Prospective evaluation of genomics-guided off-label treatment - Nature
- nature.com: Giant cancer study reveals effectiveness of ‘off label’ treatments - Nature
- Statnews: FDA panel will meet to discuss allowing broader access to certain peptides - statnews.com
- statnews.com: FDA panel will meet to discuss allowing broader access to certain peptides - statnews.com
- news.google.com: US FDA to convene expert panel to review wider access to some peptides - Reuters
- news.google.com: Amid wellness craze, FDA weighs lifting peptide restrictions - The Washington Post
- biopharmadive.com: FDA asks Lilly to evaluate obesity pill’s liver risk - BioPharma Dive
- biospace.com: Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data - BioSpace
- Bioworld: Revolution Medicines’ $1.5B follow-on highest to date - BioWorld News
- bioworld.com: Revolution Medicines’ $1.5B follow-on highest to date - BioWorld News
- wikimedia: Photo by Michael Barera / Wikimedia Commons / CC BY-SA 4.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.